References in periodicals archive ?
Rothstein is an investigator in a clinical trial of riluzole.
Riluzole has been shown to extend the survival time of individuals with ALS.
The company plans to market the riluzole oral film (ROF) under the brand name Exservan.
Riluzole, a glutamate antagonist, that has been approved by the United States Food and Drug Administration increases the survival of the patient by a couple of months if initiated at the beginning of the disease (7).
It is recommended that as soon as ALS patients with less than five years duration, no tracheostomy, and forced vital capacity (FVC) > 60% are diagnosed, they should be offered riluzole 50 mg twice a day [30, 36, 37].
Cannella et al., "Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins," European Journal of Nuclear Medicine and Molecular Imaging, vol.
Song et al., "Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells by elevated ROS production," Cancer Letters, vol.
Chow, "UPLC-MS/MS assay of riluzole in human plasma and cerebrospinal fluid (CSF): application in samples from spinal cord injured patients," Journal of Pharmaceutical and Biomedical Analysis, vol.
The first available drug, riluzole, prolongs survival by the average of 3 months, while edaravone, recently registered in Japan and US, relents disease progression in a subgroup of patients without respiratory involvement [2, 3].
Dubedat et al., "Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study," European Journal of Pharmacology, vol.